---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009791"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:50:53.676301+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx prelim 2025 revenue $672-674M beats guidance; cash $735M; two gene therapy approvals possible in 2026

## Summary
- Preliminary FY2025 total revenue $672-674M, ~20% YoY, exceeding top end of guidance.
- Crysvita revenue $480-482M (17% YoY, above guidance); Dojolvi $95-97M (9% YoY, at guidance midpoint).
- Cash and investments ~$735M at year-end 2025; full Q4/FY results and 2026 guidance due Feb 2026.
- 2026 catalysts: DTX401 (GSDIa) PDUFA Q3; UX111 (MPS IIIA) BLA resubmission early 2026; GTX-102 (Angelman) Phase 3 data H2 2026.
- UX701 (Wilson disease) pivotal data H1 2026; UX143 (osteogenesis imperfecta) data presented at JPM conference.

## SEC filing metadata
- accession: 0001193125-26-009791
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312526009791/0001193125-26-009791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312526009791/rare-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009791
- JSON: https://secwatch.observer/filing/0001193125-26-009791.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.